DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TREATMENTS
       *****************************************************
       #Post#: 4074--------------------------------------------------
       Hypogammaglobulinemia secondary to B-cell depleting strategies i
       n neuroimmunology...
       By: agate Date: June 28, 2023, 1:35 am
       ---------------------------------------------------------
       A deficiency of gammaglobulin (hypogammaglobulinemia) seems to
       mean an increased infection risk, and some people on anti-CD20
       therapies (rituximab, ocrelizumab, ocrelizumab, and ofatumumab
       are mentioned in the article) develop this condition. The
       authors (who are affiliated with Massachusetts General Hospital
       and Case Western Reserve University) conclude:
       [quote][font=open sans]Despite our small sample size and limited
       follow-up time, our results suggest that cost-effective and
       less-invasive strategies such as dose adjustments and DMT
       switches may offer safe and effective alternatives to IVIG/SCIG
       in certain patients. Large-scale prospective studies are needed
       to fully assess the safety, efficacy, and feasibility of such
       strategies in neuroimmunology patients on B-cell-depleting
       therapies.[/font][/quote]
       From Multiple Sclerosis Journal (June 22,
       2023)--"Hypogammaglobulinemia secondary to B-cell depleting
       therapies in neuroimmunology:  Comparing management strategies":
  HTML https://tinyurl.com/zerdwhyn
       *****************************************************